Toward precision medicine based on the molecular landscape of carcinoma in situ of the bronchus: is it realistic for patients with pre-invasive lung disease?
- PMID: 31245111
- PMCID: PMC6560618
- DOI: 10.21037/jtd.2019.04.87
Toward precision medicine based on the molecular landscape of carcinoma in situ of the bronchus: is it realistic for patients with pre-invasive lung disease?
Conflict of interest statement
Conflicts of Interest: P Hofman is a member of different industrial scientific advisory boards (Roche, AstraZeneca, Bristol-Myers Squibb, Pfizer, Novartis, Merck, MSD, Qiagen, Thermofischer, Biocartis) for which he receives honorarium.
Comment on
-
Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions.Nat Med. 2019 Mar;25(3):517-525. doi: 10.1038/s41591-018-0323-0. Epub 2019 Jan 21. Nat Med. 2019. PMID: 30664780 Free PMC article.
References
-
- Wisnivesky JP, Yung RC, Mathur PN, et al. Diagnosis and treatment of bronchial intraepithelial neoplasia and early lung cancer of the central airways: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e263-77S. - PubMed
Publication types
LinkOut - more resources
Full Text Sources